同仁堂医养港股IPO四次递表 净利润下滑

Core Viewpoint - Tongrentang Medical Investment Co., Ltd. is making another attempt to go public on the Hong Kong Stock Exchange after multiple delays since its initial filing in June 2024, despite having turned a profit in 2023 [1] Group 1: IPO Progress and Financial Performance - The company submitted its prospectus for the fourth time, indicating ongoing efforts to secure an IPO [1] - In the first three quarters of 2025, the company reported revenue of approximately 858 million yuan, a year-on-year increase of about 3%, while net profit decreased by 9.8% to around 24 million yuan [1][3] - The revenue growth rate has slowed significantly, dropping from approximately 26.56% in 2023 to less than 2% in 2024, with only about 3% growth in the first three quarters of 2025 [3] Group 2: Business Operations and Acquisitions - Tongrentang Medical's main business includes traditional Chinese medical services, management services, and health product sales [3] - The company has made several acquisitions, contributing significantly to its revenue, with total contributions of approximately 2 billion yuan, 3.61 billion yuan, 4.78 billion yuan, and 3.52 billion yuan from 2022 to the first three quarters of 2025, accounting for 22.1%, 31.3%, 40.7%, and 41% of total revenue respectively [4] - The company sold its stake in Shijiazhuang Tongrentang Traditional Chinese Medicine Hospital for approximately 17.1 million yuan in August 2024, which impacted net profit figures when excluding this one-time gain [4] Group 3: Profitability and Cost Structure - The net profit margin decreased from 3.2% in the first three quarters of 2024 to 2.8% in 2025, indicating declining profitability despite previous asset sales [5] - The cost of sales has been rising, with the cost of drugs and medical supplies consistently accounting for over 54% of total costs [5][6] - Employee welfare expenses have also increased, amounting to approximately 183 million yuan in the first three quarters of 2025, representing 22.6% of total costs [5][6] Group 4: Financial Health and Cash Flow - As of September 30, 2025, the company's cash and cash equivalents were approximately 225 million yuan, a decrease of about 71 million yuan from the end of 2024 [6] - The company has pledged significant equity stakes in its subsidiaries to secure bank financing, indicating reliance on external funding for capital expenditures and operational needs [6] - The asset-liability ratio increased from 39.7% in 2022 to 46.6% by September 30, 2025, reflecting a growing financial burden [7]